Coherus Oncology (CHRS) Change in Account Payables (2016 - 2025)
Historic Change in Account Payables for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$15.3 million.
- Coherus Oncology's Change in Account Payables rose 6961.49% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.1 million, marking a year-over-year increase of 2656.12%. This contributed to the annual value of -$3.9 million for FY2024, which is 11657.41% down from last year.
- Coherus Oncology's Change in Account Payables amounted to -$15.3 million in Q3 2025, which was up 6961.49% from -$12.2 million recorded in Q2 2025.
- Over the past 5 years, Coherus Oncology's Change in Account Payables peaked at $39.5 million during Q2 2024, and registered a low of -$50.4 million during Q3 2024.
- Moreover, its 5-year median value for Change in Account Payables was $616000.0 (2024), whereas its average is $88421.1.
- As far as peak fluctuations go, Coherus Oncology's Change in Account Payables crashed by 100088.2% in 2021, and later skyrocketed by 224334.98% in 2022.
- Quarter analysis of 5 years shows Coherus Oncology's Change in Account Payables stood at -$29.6 million in 2021, then soared by 105.4% to $1.6 million in 2022, then tumbled by 149.03% to -$785000.0 in 2023, then skyrocketed by 907.9% to $6.3 million in 2024, then tumbled by 341.26% to -$15.3 million in 2025.
- Its Change in Account Payables stands at -$15.3 million for Q3 2025, versus -$12.2 million for Q2 2025 and $13.0 million for Q1 2025.